1. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia
- Author
-
Terakura, S, Kuwatsuka, Y, Yamasaki, S, Wake, A, Kanda, J, Inamoto, Y, Mizuta, S, Yamaguchi, T, Uchida, N, Kouzai, Y, Aotsuka, N, Ogawa, H, Kanamori, H, Nishiwaki, K, Miyakoshi, S, Onizuka, M, Amano, I, Fukuda, T, Ichinohe, T, Atsuta, Y, Murata, M, and Teshima, T
- Abstract
To investigate better GVHD prophylaxis in reduced intensity conditioning umbilical cord blood transplantation (RIC-UCBT), we compared transplant outcomes after UCBT among GvHD prophylaxes using the registry data. We selected patients transplanted for AML or ALL with a calcineurin inhibitor and methotrexate (MTX)/mycophenolate mofetil (MMF) combination. A total of 748 first RIC-UCBT between 2000 and 2012 (MTX+ group, 446, MMF+ group, 302) were included. The cumulative incidence of neutrophil and platelet counts higher than 50 000/μL was significantly better in the MMF+ group (relative risk (RR), 1.55; P<0.001: RR, 1.34; P=0.003, respectively). In multivariate analyses, the risk of grade II–IV and III–IV acute GvHD was significantly higher in the MMF+ group than in the MTX+ group (RR, 1.75; P<0.001: RR, 1.97; P=0.004, respectively). In disease-specific analyses of AML, the risk of relapse of high-risk disease was significantly lower in the MMF+ group (RR, 0.69; P=0.009), whereas no significant difference was observed in the risk of relapse-free and overall survival in high-risk disease. In patients with standard-risk disease, no significant differences were noted in the risk of relapse or survival between the MTX+ and MMF+ groups. Collectively, these results suggest that MMF-containing prophylaxis may be preferable in RIC-UCBT, particularly for high-risk disease.
- Published
- 2017
- Full Text
- View/download PDF